Gujarat Kidney and Super Speciality Ltd has fixed the price band of ₹ 108/- to ₹ 114/- per Equity Share of face value ₹ 2/- each for its maiden initial public offer. The Initial Public Issue of the Company will open on Monday, December 22, 2025, for subscription and close on Wednesday, December 24, 2025. Investors can bid for a minimum of 128 Equity Shares and in multiples of 128 Equity Shares thereafter.
- Issue Opens: December 22, 2025
- Issue Closes: December 24, 2025
- Face Value: Rs 2 each
- Price Band: Rs 108 – 114 per share
- Lot Size: 128 Shares
- Listing: BSE NSE
Equity shares outstanding as on date 5,68,43,250 Equity Shares of Rs 2 each. The IPO is a fresh issue of up to 2,20,00,000 equity shares. The company is one of the regional healthcare companies located in the central region of Gujarat and operates a chain of mid-sized multi-speciality hospitals, providing integrated healthcare services, with a focus on secondary and tertiary care.
We on a consolidated basis, operate seven (07) multispeciality hospitals and four (04) pharmacies operating within our Hospitals, Gujarat Kidney and Superspeciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited (Bharuch), M/s. Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), Ashwini Medical Centre (Anand), Ashwini Medical Store (Anand) and Apex Multispeciality & Trauma Center (Bharuch) with a total bed capacity of 490 beds, approved bed capacity of 445 beds and operational bed capacity of 340 beds.
The company categorizes its healthcare services as secondary services (which are surgical services) and tertiary Services (which are super speciality surgical services). Its hospitals are providing integrated diagnostic services, either in-house, and pharmacies that cater to its patients. The company has strategically focused on the relatively underpenetrated healthcare market in Gujarat, India, where it has a presence in four cities, which it believes has provided it an understanding of regional nuances, patient culture and the mindset of medical professionals and where there is under-penetration of quality and affordable healthcare services.
The company’s revenue from operations was Rs 40.24 crore during the year ended on March 31, 2025, and its net profit was Rs9.49 crore. The company’s revenue from operations was Rs 15.26 crore during the three-month period ended June 30, 2025, and its net profit was Rs 5.40 crore.
